ArticleJournal of the American Heart Association2025
Predictors of Long-Term Survival in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Immune checkpoint inhibitor-related myositis, myocarditis, and myasthenia gravis overlap syndrome: a systematic review and pooled analysis of individual cases.Frontiers in immunology · 2026Pooled it
- Troponin for surveillance of immune checkpoint inhibitor-associated myocarditis and post-therapy cardiovascular risk stratification: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Pooled it
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Circulating Biomarkers in Cardio-Oncology: Prediction and Prognostication.Current cardiology reports · 2026Review
- Early lymphocyte recovery predicts cardiovascular events and mortality in immune checkpoint inhibitor-associated myocarditis: a retrospective cohort study.Frontiers in cardiovascular medicine · 2026Article
- Risk elements and diagnostic indicators for asymptomatic immune checkpoint inhibitor-associated myocarditis in esophageal cancer.World journal of gastroenterology · 2025Article
- Inflammatory index-based nomogram for risk stratification of erectile dysfunction: a cross-sectional study with dual-cohort validation and mendelian randomization analysis.Translational andrology and urology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmune checkpoint inhibitor-associated myocarditis (ICIM) carries high rates of morbidity and death, but clinical outcomes vary widely. Little is known about the clinical variables associated with long-term survival.
methodsIn this case-control study, patients diagnosed with ICIM at Massachusetts General Hospital between 2016 and 2022 were stratified into 3 groups based on length of survival after ICIM diagnosis: short-term (<30 days), intermediate-term (30-365 days), and long-term (>365 days). Baseline characteristics, immune checkpoint inhibitor regimens, laboratory values, ECG parameters, and ICIM treatments were analyzed to identify predictors of long-term survival.
resultsAmong 35 patients with ICIM (median follow-up time, 8.3 months), there were 9 (25.7%) in the short-term survival group, 13 (37.1%) in the intermediate-term survival group, and 13 (37.1%) in the long-term survival group. Those in the short-term survival group were older (median age, 82 versus 68 for intermediate-term and 75 for long-term;
conclusionsTime to onset of ICIM, multiple clinical tests, and responsiveness to immunosuppressive therapy were associated with long-term survival after ICIM. Consideration of these variables may help with risk stratification and immunosuppressive therapy individualization.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.